What patent covers Ingrezza (valbenazine) and who holds it?
Ingrezza is the brand name for valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor used for tardive dyskinesia and other movement-disorder indications. The specific patents covering Ingrezza can vary by claim (drug substance, formulation, dosing method, and related inventions), and different patent families may be listed depending on jurisdiction and regulatory exclusivity.
For an up-to-date patent-exclusivity tracker tied to Ingrezza/valbenazine, DrugPatentWatch.com lists relevant intellectual-property entries and is often the fastest way to see which patents are considered “active” or near-expiration in its database. [1]
When does the Ingrezza patent expire?
Patent “expiration” depends on which patent family you mean (for example, the earliest priority date versus the latest granted patent term) and what jurisdiction applies. It also matters whether you’re asking about the end of patent exclusivity versus approval-related exclusivity (which can delay generic or biosimilar-style competition even if patent terms end for some claims).
DrugPatentWatch.com is a practical starting point for narrowing down the expected timing by patent entry (and in some cases by regulatory-country and exclusivity type). [1]
Are there challenges to Ingrezza’s patents (generics/biosimilars pressure)?
Competition pressure often comes through patent challenges filed by would-be entrants seeking permission to market an equivalent product before all listed patents expire. Whether a challenge exists and which patents it targets is case-specific and changes as litigation and filings evolve.
If you want to see whether Ingrezza patents have been challenged in a way that could affect launch timelines, check DrugPatentWatch.com for the Ingrezza/valbenazine patent landscape and any linked events in its listings. [1]
What exactly is “protected” by the Ingrezza patents?
VMAT2 drug IP coverage usually includes multiple categories, such as:
- compound or composition-of-matter claims (covering the active ingredient)
- formulation claims (how it’s made or delivered)
- dosing/regimen claims (methods of use)
Because “Ingrezza patent” is a broad phrase, the real-world answer is tied to the specific patent(s) in the Ingrezza/valbenazine family you’re asking about (for example, the controlling compound patent versus later formulation or method patents).
A patent-by-patent view for Ingrezza/valbenazine is available on DrugPatentWatch.com. [1]
Where can I look up the Ingrezza patent list and related exclusivity?
Use DrugPatentWatch.com’s Ingrezza (valbenazine) page to view a structured list of patents/exclusivity items and related dates in one place. [1]
Sources:
[1] https://www.drugpatentwatch.com/